

# Wisconsin Drug Utilization Review Board Meeting

- March 2, 2011



# Changes to Retrospective Drug Utilization Review

- Health Information Design (HID) Current Process
  - HID reviews all new drugs and assigns a risk score of minor (severity level 3), moderate (severity level 2) or major (severity level 1) to potential adverse issues
  - HID periodically reviews for the addition of new drug-drug interactions, precautions and contraindications
  - All criteria is available to states



# Retrospective Drug Utilization Review

HID criteria available

Wisconsin criteria
--------------------



# Wisconsin's Current Process

- Criteria based
  - 1,000 profiles are reviewed monthly
  - On Average 12 criteria are reviewed



# Recommended Process

- Automate certain criteria additions
- Switch to member risk based for selecting profiles for review
- This change both increases use of high risk criteria and reviews members with highest risk scores regardless of criteria that caused it



# HID System Calculation of Profile Risk Score:

- A numerical Risk Value is calculated using multiple factors.
  - Base Risk Value based on the Severity Level of the drug-related problem
  - Addition of Risk Value based on # of pharmacies
  - Addition of Risk Value based on # of physicians
  - Addition of Risk Value based on patient sex
  - Addition of Risk Value based on patient age

A Total Patient Risk Score is determined for each patient by totaling all Risk Values.



# Therapeutic Criteria Categories

1. **Drug-Drug Interactions**
2. **Drug-Disease Interactions**
3. **Therapeutic Duplication**
4. **Therapeutic Appropriateness**
5. **Disease State Management**



# Drug-Drug Interactions

- Identifies patients who are receiving two or more drugs, that when taken together, can cause unpredictable or undesirable effects.
- DHS recommendation:
  - Automatically add new Severity Level 1 criteria as available
  - Activate currently available Severity Level 1 criteria





# Drug-Disease Interactions

- Identifies patients who are receiving drugs that may worsen or precipitate medical conditions. The medical condition is identified by either a drug marker for the condition or by a diagnosis for which a provider is billing.
- DHS Recommendation:
  - Automatically add new Severity Level 1 criteria as available
  - Activate currently available Severity Level 1 criteria



# Therapeutic Duplication

- Identifies patients who are receiving two or more drugs from the same therapeutic class. This duplication could cause unpredictable or undesirable effects.
- DHS Recommendation:
  - Automatically add new Severity Level 1 criteria as available
  - Activate currently available Severity Level 1 criteria



# Therapeutic Appropriateness

- Identifies patients who are receiving drugs or not receiving drugs in accordance to their age, diagnosis or lack of diagnosis. This could mean that the patient has a diagnosis and may benefit from an addition of a drug. It could also mean that a patient is receiving a drug and does not have an appropriate diagnosis for the drug. The diagnosis could be identified by drugs received or by diagnosis billed by provider.
- DHS Recommendation:
  - Automatically add new Severity Level 1 criteria as available
  - Activate currently available Severity Level 1 criteria



# Disease State Management

- Identifies patients with chronic health problems, recommends additional therapy that would benefit the patient.
- DHS Recommendation:
  - Add new Severity Level 1 criteria as available, but flag for State review to determine if therapy recommendations conflict with other State policy (e.g. PDL, PA). Can be deleted if necessary.
  - Activate current Severity Level 1 criteria with State approval



# Utilization Management Criteria

1. **Over-Utilization**
2. **Under-Utilization**
3. **Drug-Age**
4. **Drug-Pregnancy**
5. **Contraindications**
6. **Black Box Warnings**



# Over-Utilization

- Identifies patients who receive drugs at excessive dosage levels or for inappropriately extended periods of time. These patients are at elevated unnecessary risk for adverse reactions and drug-induced disease.
- DHS Recommendation:
  - Do not add additional early refill (ER) criteria
  - Discontinue current early refill criteria
  - Automatically add Severity Level 1 criteria that is classified *other than ER*, as available
  - Activate currently available Severity Level 1 criteria *except for ER*



# Under Utilization

- Identifies patients who might be non-compliant with their maintenance medication. Under-utilization of drugs prescribed for the treatment of chronic conditions such as seizure disorders, hypertension, and diabetes places patients at unnecessary risk for increased morbidity and mortality.
- DHS Recommendation:
  - Keep current late refill (LR) criteria approved at 6/2010 DUR Board meeting
  - Automatically add LR criteria as available for new drugs in therapeutic classes for chronic diseases such as HTN, diabetes, asthma, psychosis and depression, HIV/AIDS, immunotherapy, dyslipidemia, epilepsy
  - Activate Severity Level 1 criteria.



# Drug-Age

- Identifies patients who may be at risk for adverse effects from certain drugs because of their age.
- DHS Recommendation:
  - Automatically add new Severity Level 1 criteria as available
  - Activate current Severity Level 1 criteria





# Drug-Pregnancy

- Identifies patients who may be at risk for teratogenic effects or pregnancy complications from the use of certain drugs.
- DHS Recommendation:
  - Keep current drug/pregnancy criteria, including criteria using pre-natal vitamins as proxy marker for pregnant state as well as actual diagnosis
  - Automatically add drug/pregnancy criteria as available.
  - Activate Severity Level 1 criteria.



# Contraindications

- All contraindications are ranked as a major Severity Level 1.
- DHS Recommendation:
  - Automatically add new Severity Level 1 criteria as available
  - Activate currently available Severity Level 1 criteria



# Black Box Warnings

- Black Box Warning-based criteria are Severity Level 1.
- Some of these criteria require both the warned drug and either an additional drug or diagnosis to hit.
- Some of these criteria require only the warned drug to be present to hit.
- DHS Recommendation:
  - Automatically add new Severity Level 1 criteria as available
  - Activate current Severity Level 1 criteria




# Opioid Prescription Limits

- Distinct Number of Members Who Hit the Audit:
  - 1/1/11 – 1/31/11: 468
  - 2/1/11 – 2/20/11: 60
- Number of Approved PAs:
  - 1/1/11 – 1/31/11: 252
  - 2/1/11 – 2/20/11: 38
- Currently exempt antitussives



# Suboxone/Subutex Use with Opioids

Suboxone/Subutex Use with Opioids Criteria



# Pharmacy Services Lock-In Restructuring

- Implementation April 1, 2011



# Targeted Intervention Updates

- Antipsychotic interventions – letters and attestation process
- Low dose antipsychotic use



# Focus for Next Meeting for Drug Utilization Management

- Prospective Drug Utilization Review
- President's Budget
- Board suggestions

